What is Intra-Cellular Therapies Caplyta?

Intra-Cellular Therapies Caplyta is an antipsychotic drug used in the treatment of schizophrenia in adults. It was approved by the U.S. Food and Drug Administration (FDA) in December 2019. The drug's active ingredient is lumateperone, and it works by modulating serotonin, dopamine, and glutamate neurotransmitter systems in the brain.

Caplyta is manufactured by Intra-Cellular Therapies, Inc., a biopharmaceutical company based in New York City that focuses on the development of innovative therapies for the treatment of neuropsychiatric and neurodegenerative disorders. The company is also known for its patient assistance program, which helps eligible patients access Caplyta who do not have insurance.

Since its approval, Caplyta has seen significant market growth. In 2020, the U.S. antipsychotic drug market was valued at over $12 billion, and Caplyta has the potential to become a blockbuster drug, with an estimated annual revenue of $700 million in the U.S. alone.

In addition to its efficacy in treating schizophrenia, Caplyta has also been found to be well-tolerated by patients, with fewer side effects compared to other antipsychotic drugs. The drug has also undergone several clinical trials, with positive results showing significant improvement in patients' symptoms.

In summary, Intra-Cellular Therapies Caplyta is a promising treatment for schizophrenia that has been approved by the FDA and has seen significant market growth. The drug's manufacturer, Intra-Cellular Therapies, Inc., is dedicated to the development of innovative therapies for neuropsychiatric and neurodegenerative disorders and offers a patient assistance program for eligible patients.